Runben Biotechnology Co., Ltd. (SHA:603193)

Runben Biotechnology Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 14, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	9,917	9,447	7,356	-	-	-
Market Cap Growth	-26.94%	28.44%	-	-	-	-
Enterprise Value	8,787	9,054	6,808	-	-	-
Last Close Price	24.51	23.05	17.66	-	-	-
PE Ratio	32.29	31.47	32.54	-	-	-
Forward PE	29.41	26.27	26.80	-	-	-
PS Ratio	6.53	7.17	7.12	-	-	-
PB Ratio	4.56	4.54	3.83	-	-	-
P/TBV Ratio	4.76	4.66	3.87	-	-	-
P/FCF Ratio	50.94	51.62	30.79	-	-	-
P/OCF Ratio	33.31	36.73	29.13	-	-	-
EV/Sales Ratio	5.79	6.87	6.59	-	-	-
EV/EBITDA Ratio	24.91	27.62	25.94	-	-	-
EV/EBIT Ratio	26.47	29.38	28.06	-	-	-
EV/FCF Ratio	45.14	49.47	28.50	-	-	-
Debt / Equity Ratio	0.00	0.00	0.00	0.01	0.02	-
Debt / EBITDA Ratio	0.00	0.01	0.02	0.04	0.07	-
Debt / FCF Ratio	0.01	0.02	0.02	0.06	-	-
Net Debt / Equity Ratio	-0.52	-0.69	-0.83	-0.51	-0.45	-0.33
Net Debt / EBITDA Ratio	-3.21	-4.36	-6.09	-1.89	-1.82	-0.71
Net Debt / FCF Ratio	-5.80	-7.82	-6.69	-2.96	18.84	-2.82
Asset Turnover	0.67	0.62	0.73	1.16	1.26	2.01
Inventory Turnover	4.93	5.23	4.64	4.93	5.40	5.64
Quick Ratio	9.02	10.58	16.93	3.97	3.64	3.72
Current Ratio	12.51	11.63	18.04	5.28	4.56	5.85
Return on Equity (ROE)	14.49%	15.00%	17.10%	24.93%	29.72%	48.88%
Return on Assets (ROA)	9.17%	9.09%	10.66%	15.06%	17.69%	30.29%
Return on Invested Capital (ROIC)	31.14%	54.09%	60.54%	45.44%	45.56%	67.89%
Return on Capital Employed (ROCE)	15.20%	14.80%	12.60%	24.30%	22.90%	42.40%
Earnings Yield	3.08%	3.18%	3.07%	-	-	-
FCF Yield	1.96%	1.94%	3.25%	-	-	-
Dividend Yield	1.93%	1.78%	0.96%	-	-	-
Payout Ratio	79.01%	45.32%	-	2.15%	25.65%	-
Buyback Yield / Dilution	0.23%	-14.85%	-3.71%	-1.61%	-9.69%	-499.54%
Total Shareholder Return	2.13%	-13.07%	-2.75%	-1.61%	-9.69%	-499.54%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.